Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 167 clinical trials
Featured trial
A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®

A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and

  • 607 views
  • 23 Nov, 2020
  • 1 location
Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

Natural killer/T-cell lymphoma (NKTCL) patients with relapsed/refractory disease had very poor outcome. Anti-PD-1 antibody showed promising results in response, but but the complete remission

  • 0 views
  • 03 Oct, 2021
  • 1 location
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese sites. All eligible patients will be treated with standard radiotherapy

  • 0 views
  • 21 Apr, 2022
  • 1 location
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in newly-diagnosed T-NHL.

prednisone
peripheral t-cell lymphoma
ct scan
measurable disease
etoposide
  • 3 views
  • 23 Feb, 2022
  • 2 locations
Tislelizumab Combined With Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma

combination treatment in patients with relapsed or refractory Extranodal Natural Killer/T Cell Lymphoma(NKTCL)

  • 0 views
  • 04 Oct, 2022
  • 3 locations
  • 0 views
  • 24 Oct, 2022
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.

  • 0 views
  • 07 Jul, 2022
  • 1 location
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell

  • 0 views
  • 24 Jan, 2021
  • 1 location
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL (PTCL)

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study

  • 5 views
  • 13 Mar, 2022
  • 3 locations
  • 1 views
  • 17 Oct, 2022
  • 7 locations